A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip Pravin Patel(University of California San Diego), Razelle Kurzrock(Medical College of Wisconsin), Anup Kasi(University of Kansas Medical Center), Edward Mayerson(Cancer Research And Biostatistics), Elad Sharon(National Cancer Institute), Megan Othus(Cancer Research And Biostatistics), Manisha H. Shah(Pakistan Institute of Medical Sciences), Charles D. Blanke(SWOG Cancer Research Network), Zoran Gatalica(Credo Reference (United States)), Annette Campbell Fontaine(New Mexico Cancer Center), W. Michael Korn(Itasca Community College), Melissa Plets(Cancer Research And Biostatistics), Christopher W. Ryan(Oregon Health & Science University), Marc Matrana(Ochsner Medical Center), Francis J. Giles(National University of Ireland), Tareq Al Baghdadi(IHA Hematology Oncology Consultants), Preet Paul Singh, Young Kwang Chae(Northwestern University), Christine M. McLeod(SWOG Cancer Research Network), Jourdain Hayward(SWOG Cancer Research Network), Helen X. Chen(National Cancer Institute), Donna E. Hansel(The University of Texas MD Anderson Cancer Center)
Cited by 326
Related Papers
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k